title: Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer.
abstract: Epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors are useful in treating different advanced human cancers; however, their clinical efficacy varies. This study detected K-ras mutations to predict the efficacy of EGFR-TK inhibitor cetuximab treatment on Chinese patients with metastatic colorectal cancer (mCRC). A total of 87 patients with metastatic colorectal cancer were treated with cetuximab for 2-16 months, in combination with chemotherapy between August 2008 and July 2012, and tissue samples were used to detect K-ras mutations. The data showed that K-ras mutation occurred in 27/87 (31%). The objective response rates and disease control rate in K-ras wild type and mutant patients were 42% (25/60) versus 11% (3/27) (p<0.05) and 60% (36/60) versus 26% (7/27) (p<0.05), respectively. Patients with the wild-type K-ras had significantly higher median survival times and progression-free survival, than patients with mutated K-ras (21 months versus 17 months, p=0.017; 10 months versus 6 months, p=0.6). These findings suggest that a high frequency of K-ras mutations occurs in Chinese mCRC patients and that K-ras mutation is required to select patients for eligibility for cetuximab therapy. Further prospective studies using a large sample size are needed to confirm these preliminary findings.
authors.affiliation: Department of Gastrointestinal Surgery, Cancer Hospital of Jilin Province, Changchun, Jilin, China.
authors.forename: Ze
authors.initials: Z
authors.lastname: Li
authors.affiliation: Department of Gastrointestinal Surgery, Cancer Hospital of Jilin Province, Changchun, Jilin, China.
authors.forename: Xue-Wei
authors.initials: XW
authors.lastname: Liu
authors.affiliation: Department of Gastrointestinal Surgery, Cancer Hospital of Jilin Province, Changchun, Jilin, China.
authors.forename: Zhao-Cheng
authors.initials: ZC
authors.lastname: Chi
authors.affiliation: Department of Gastrointestinal Surgery, Cancer Hospital of Jilin Province, Changchun, Jilin, China.
authors.forename: Bao-Sheng
authors.initials: BS
authors.lastname: Sun
authors.affiliation: Department of Gastrointestinal Surgery, Cancer Hospital of Jilin Province, Changchun, Jilin, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Cheng
authors.affiliation: Department of Gastrointestinal Surgery, Cancer Hospital of Jilin Province, Changchun, Jilin, China.
authors.forename: Long-Wei
authors.initials: LW
authors.lastname: Cheng
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D044466:Asian People / Q000235:genetics*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068818:Cetuximab / Q000008:administration & dosage*; D002681:China; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; C117307:KRAS protein, human; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D016283:Proto-Oncogene Proteins p21(ras); D000068818:Cetuximab; D002166:Camptothecin